211 related articles for article (PubMed ID: 37019471)
1. Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases.
Yang A; Zhang Z; Chaurasiya S; Park AK; Jung A; Lu J; Kim SI; Priceman S; Fong Y; Woo Y
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37019471
[TBL] [Abstract][Full Text] [Related]
2. Novel Chimeric Immuno-Oncolytic Virus CF33-hNIS-antiPDL1 for the Treatment of Pancreatic Cancer.
Woo Y; Zhang Z; Yang A; Chaurasiya S; Park AK; Lu J; Kim SI; Warner SG; Von Hoff D; Fong Y
J Am Coll Surg; 2020 Apr; 230(4):709-717. PubMed ID: 32032721
[TBL] [Abstract][Full Text] [Related]
3. Anti-Tumor Immunogenicity of the Oncolytic Virus CF33-hNIS-antiPDL1 against Ex Vivo Peritoneal Cells from Gastric Cancer Patients.
Zhang Z; Yang A; Chaurasiya S; Park AK; Kim SI; Lu J; Valencia H; Fong Y; Woo Y
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762490
[TBL] [Abstract][Full Text] [Related]
4. CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy.
Zhang Z; Yang A; Chaurasiya S; Park AK; Lu J; Kim SI; Warner SG; Yuan YC; Liu Z; Han H; Von Hoff D; Fong Y; Woo Y
Cancer Gene Ther; 2022 Jun; 29(6):722-733. PubMed ID: 34108669
[TBL] [Abstract][Full Text] [Related]
5. PET imaging and treatment of pancreatic cancer peritoneal carcinomatosis after subcutaneous intratumoral administration of a novel oncolytic virus, CF33-hNIS-antiPDL1.
Zhang Z; Yang A; Chaurasiya S; Park AK; Kim SI; Lu J; Olafsen T; Warner SG; Fong Y; Woo Y
Mol Ther Oncolytics; 2022 Mar; 24():331-339. PubMed ID: 35118191
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model.
Chaurasiya S; Yang A; Kang S; Lu J; Kim SI; Park AK; Sivanandam V; Zhang Z; Woo Y; Warner SG; Fong Y
Oncoimmunology; 2020; 9(1):1729300. PubMed ID: 32158622
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive preclinical study supporting clinical trial of oncolytic chimeric poxvirus CF33-hNIS-anti-PD-L1 to treat breast cancer.
Chaurasiya S; Yang A; Zhang Z; Lu J; Valencia H; Kim SI; Woo Y; Warner SG; Olafsen T; Zhao Y; Wu X; Fein S; Cheng L; Cheng M; Ede N; Fong Y
Mol Ther Methods Clin Dev; 2022 Mar; 24():102-116. PubMed ID: 35024377
[TBL] [Abstract][Full Text] [Related]
8. Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer.
Song KY; Wong J; Gonzalez L; Sheng G; Zamarin D; Fong Y
J Mol Med (Berl); 2010 Jun; 88(6):589-96. PubMed ID: 20393691
[TBL] [Abstract][Full Text] [Related]
9. Peritoneal-directed chimeric oncolytic virus CF17 prevents malignant ascites and improves survival in gastric cancer peritoneal metastases.
Yang A; Zhang Z; Chaurasiya S; Park AK; Lu J; Kim SI; Valencia H; Fong Y; Woo Y
Mol Ther Oncolytics; 2023 Dec; 31():100734. PubMed ID: 37915757
[TBL] [Abstract][Full Text] [Related]
10. Regional administration of oncolytic Echovirus 1 as a novel therapy for the peritoneal dissemination of gastric cancer.
Haley ES; Au GG; Carlton BR; Barry RD; Shafren DR
J Mol Med (Berl); 2009 Apr; 87(4):385-99. PubMed ID: 19139835
[TBL] [Abstract][Full Text] [Related]
11. An oncolytic poxvirus encoding hNIS, shows anti-tumor efficacy and allows tumor imaging in a liver cancer model.
Chaurasiya S; Valencia H; Zhang Z; Kim SI; Yang A; Lu J; Woo Y; Warner SG; Ede NJ; Fong Y
Mol Cancer Ther; 2023 May; 22(7):882-90. PubMed ID: 37196156
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of oncolytic reovirus against human gastric cancer with peritoneal metastasis in experimental animal model.
Kawaguchi K; Etoh T; Suzuki K; Mitui MT; Nishizono A; Shiraishi N; Kitano S
Int J Oncol; 2010 Dec; 37(6):1433-8. PubMed ID: 21042711
[TBL] [Abstract][Full Text] [Related]
13. A novel oncolytic viral therapy and imaging technique for gastric cancer using a genetically engineered vaccinia virus carrying the human sodium iodide symporter.
Jun KH; Gholami S; Song TJ; Au J; Haddad D; Carson J; Chen CH; Mojica K; Zanzonico P; Chen NG; Zhang Q; Szalay A; Fong Y
J Exp Clin Cancer Res; 2014 Jan; 33(1):2. PubMed ID: 24383569
[TBL] [Abstract][Full Text] [Related]
14. An Oncolytic Poxvirus Encoding hNIS, Shows Antitumor Efficacy and Allows Tumor Imaging in a Liver Cancer Model.
Chaurasiya S; Valencia H; Zhang Z; Kim SI; Yang A; Lu J; Woo Y; Warner SG; Ede NJ; Fong Y
Mol Cancer Ther; 2023 Jun; ():OF1-OF9. PubMed ID: 37294888
[TBL] [Abstract][Full Text] [Related]
15. A chimeric poxvirus with J2R (thymidine kinase) deletion shows safety and anti-tumor activity in lung cancer models.
Chaurasiya S; Chen NG; Lu J; Martin N; Shen Y; Kim SI; Warner SG; Woo Y; Fong Y
Cancer Gene Ther; 2020 Apr; 27(3-4):125-135. PubMed ID: 31209267
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy using therapeutic and diagnostic recombinant oncolytic vaccinia virus GLV-1h153 for management of colorectal peritoneal carcinomatosis.
Eveno C; Mojica K; Ady JW; Thorek DL; Longo V; Belin LJ; Gholami S; Johnsen C; Zanzonico P; Chen N; Yu T; Szalay AA; Fong Y
Surgery; 2015 Feb; 157(2):331-7. PubMed ID: 25616946
[TBL] [Abstract][Full Text] [Related]
17. Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus.
Haddad D; Chen NG; Zhang Q; Chen CH; Yu YA; Gonzalez L; Carpenter SG; Carson J; Au J; Mittra A; Gonen M; Zanzonico PB; Fong Y; Szalay AA
J Transl Med; 2011 Mar; 9():36. PubMed ID: 21453532
[TBL] [Abstract][Full Text] [Related]
18. Enhancing Expression of Functional Human Sodium Iodide Symporter and Somatostatin Receptor in Recombinant Oncolytic Vaccinia Virus for In Vivo Imaging of Tumors.
Wang J; Arulanandam R; Wassenaar R; Falls T; Petryk J; Paget J; Garson K; Cemeus C; Vanderhyden BC; Wells RG; Bell JC; Le Boeuf F
J Nucl Med; 2017 Feb; 58(2):221-227. PubMed ID: 27635026
[TBL] [Abstract][Full Text] [Related]
19. Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.
Nanni P; Gatta V; Menotti L; De Giovanni C; Ianzano M; Palladini A; Grosso V; Dall'ora M; Croci S; Nicoletti G; Landuzzi L; Iezzi M; Campadelli-Fiume G; Lollini PL
PLoS Pathog; 2013 Jan; 9(1):e1003155. PubMed ID: 23382683
[TBL] [Abstract][Full Text] [Related]
20. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
